Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia

Bradford D. Gessner, Endang R. Sedyaningsih, Ulla K. Griffiths, Agustinus Sutanto, Mary Linehan, Dave Mercer, Edward Kim Mulholland, Damian G. Walker, Mark Steinhoff, Mardiati Nadjib

Research output: Contribution to journalArticle

Abstract

Background: Most of Asia, including Indonesia, does not use Haemophilus influenzae type b (Hib) conjugate vaccines. We estimated total vaccine-preventable disease burden and the cost-effectiveness of Hib conjugate vaccine in Indonesia. Methods: Hib pneumonia and meningitis incidences for children with access to health care were derived from a randomized vaccine probe study on Lombok Island, Indonesia during 1998 "2002. Incidences were adjusted for limited access to care. Health system and patient out-of-pocket treatment cost data were collected concurrent with the probe study. For Hib vaccine in monovalent and combined (with DTP-HepB) presentations, we used 2007 UNICEF vaccine prices of US$3.30 and $3.75 per dose. Results: For the 2007 Indonesian birth cohort, Hib vaccine would prevent meningitis in 1 of every 179 children, pneumonia in 1 of every 18 children, and 4.9% of mortality among those younger than 5 years. The total incremental societal costs of introducing Hib vaccine in monovalent and pentavalent presentations were, respectively, US$11.74 and $8.93 per child vaccinated. Annual discounted treatment costs averted amounted to 20% of pentavalent vaccine costs. For the pentavalent vaccine, the incremental costs per discounted death and disability adjusted life-year averted amounted to US$3102 and $74, respectively, versus $4438 and $102 for monovalent vaccine. Conclusions: Routine infant Hib vaccination would prevent a large burden of pediatric illness and death in Indonesia. Even without external funding support, Hib vaccine will be a highly cost-effective intervention in either a monovalent or pentavalent presentation based on commonly used benchmarks.

Original languageEnglish (US)
Pages (from-to)438-443
Number of pages6
JournalPediatric Infectious Disease Journal
Volume27
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Haemophilus Vaccines
Haemophilus influenzae type b
Cost of Illness
Indonesia
Cost-Benefit Analysis
Vaccination
Vaccines
Costs and Cost Analysis
Conjugate Vaccines
Meningitis
Health Care Costs
Pneumonia
Benchmarking
Child Mortality
Health Services Accessibility
Quality-Adjusted Life Years
United Nations
Incidence
Health Expenditures
Islands

Keywords

  • cost effectiveness
  • Haemophilus influenzae type b
  • Indonesia
  • vaccine
  • vaccine effectiveness

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Gessner, B. D., Sedyaningsih, E. R., Griffiths, U. K., Sutanto, A., Linehan, M., Mercer, D., ... Nadjib, M. (2008). Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia. Pediatric Infectious Disease Journal, 27(5), 438-443. https://doi.org/10.1097/INF.0b013e318165f1ba

Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia. / Gessner, Bradford D.; Sedyaningsih, Endang R.; Griffiths, Ulla K.; Sutanto, Agustinus; Linehan, Mary; Mercer, Dave; Mulholland, Edward Kim; Walker, Damian G.; Steinhoff, Mark; Nadjib, Mardiati.

In: Pediatric Infectious Disease Journal, Vol. 27, No. 5, 05.2008, p. 438-443.

Research output: Contribution to journalArticle

Gessner, BD, Sedyaningsih, ER, Griffiths, UK, Sutanto, A, Linehan, M, Mercer, D, Mulholland, EK, Walker, DG, Steinhoff, M & Nadjib, M 2008, 'Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia', Pediatric Infectious Disease Journal, vol. 27, no. 5, pp. 438-443. https://doi.org/10.1097/INF.0b013e318165f1ba
Gessner, Bradford D. ; Sedyaningsih, Endang R. ; Griffiths, Ulla K. ; Sutanto, Agustinus ; Linehan, Mary ; Mercer, Dave ; Mulholland, Edward Kim ; Walker, Damian G. ; Steinhoff, Mark ; Nadjib, Mardiati. / Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia. In: Pediatric Infectious Disease Journal. 2008 ; Vol. 27, No. 5. pp. 438-443.
@article{8b40c0a0052946ad9ba5f23c200685d4,
title = "Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia",
abstract = "Background: Most of Asia, including Indonesia, does not use Haemophilus influenzae type b (Hib) conjugate vaccines. We estimated total vaccine-preventable disease burden and the cost-effectiveness of Hib conjugate vaccine in Indonesia. Methods: Hib pneumonia and meningitis incidences for children with access to health care were derived from a randomized vaccine probe study on Lombok Island, Indonesia during 1998 {"}2002. Incidences were adjusted for limited access to care. Health system and patient out-of-pocket treatment cost data were collected concurrent with the probe study. For Hib vaccine in monovalent and combined (with DTP-HepB) presentations, we used 2007 UNICEF vaccine prices of US$3.30 and $3.75 per dose. Results: For the 2007 Indonesian birth cohort, Hib vaccine would prevent meningitis in 1 of every 179 children, pneumonia in 1 of every 18 children, and 4.9{\%} of mortality among those younger than 5 years. The total incremental societal costs of introducing Hib vaccine in monovalent and pentavalent presentations were, respectively, US$11.74 and $8.93 per child vaccinated. Annual discounted treatment costs averted amounted to 20{\%} of pentavalent vaccine costs. For the pentavalent vaccine, the incremental costs per discounted death and disability adjusted life-year averted amounted to US$3102 and $74, respectively, versus $4438 and $102 for monovalent vaccine. Conclusions: Routine infant Hib vaccination would prevent a large burden of pediatric illness and death in Indonesia. Even without external funding support, Hib vaccine will be a highly cost-effective intervention in either a monovalent or pentavalent presentation based on commonly used benchmarks.",
keywords = "cost effectiveness, Haemophilus influenzae type b, Indonesia, vaccine, vaccine effectiveness",
author = "Gessner, {Bradford D.} and Sedyaningsih, {Endang R.} and Griffiths, {Ulla K.} and Agustinus Sutanto and Mary Linehan and Dave Mercer and Mulholland, {Edward Kim} and Walker, {Damian G.} and Mark Steinhoff and Mardiati Nadjib",
year = "2008",
month = "5",
doi = "10.1097/INF.0b013e318165f1ba",
language = "English (US)",
volume = "27",
pages = "438--443",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia

AU - Gessner, Bradford D.

AU - Sedyaningsih, Endang R.

AU - Griffiths, Ulla K.

AU - Sutanto, Agustinus

AU - Linehan, Mary

AU - Mercer, Dave

AU - Mulholland, Edward Kim

AU - Walker, Damian G.

AU - Steinhoff, Mark

AU - Nadjib, Mardiati

PY - 2008/5

Y1 - 2008/5

N2 - Background: Most of Asia, including Indonesia, does not use Haemophilus influenzae type b (Hib) conjugate vaccines. We estimated total vaccine-preventable disease burden and the cost-effectiveness of Hib conjugate vaccine in Indonesia. Methods: Hib pneumonia and meningitis incidences for children with access to health care were derived from a randomized vaccine probe study on Lombok Island, Indonesia during 1998 "2002. Incidences were adjusted for limited access to care. Health system and patient out-of-pocket treatment cost data were collected concurrent with the probe study. For Hib vaccine in monovalent and combined (with DTP-HepB) presentations, we used 2007 UNICEF vaccine prices of US$3.30 and $3.75 per dose. Results: For the 2007 Indonesian birth cohort, Hib vaccine would prevent meningitis in 1 of every 179 children, pneumonia in 1 of every 18 children, and 4.9% of mortality among those younger than 5 years. The total incremental societal costs of introducing Hib vaccine in monovalent and pentavalent presentations were, respectively, US$11.74 and $8.93 per child vaccinated. Annual discounted treatment costs averted amounted to 20% of pentavalent vaccine costs. For the pentavalent vaccine, the incremental costs per discounted death and disability adjusted life-year averted amounted to US$3102 and $74, respectively, versus $4438 and $102 for monovalent vaccine. Conclusions: Routine infant Hib vaccination would prevent a large burden of pediatric illness and death in Indonesia. Even without external funding support, Hib vaccine will be a highly cost-effective intervention in either a monovalent or pentavalent presentation based on commonly used benchmarks.

AB - Background: Most of Asia, including Indonesia, does not use Haemophilus influenzae type b (Hib) conjugate vaccines. We estimated total vaccine-preventable disease burden and the cost-effectiveness of Hib conjugate vaccine in Indonesia. Methods: Hib pneumonia and meningitis incidences for children with access to health care were derived from a randomized vaccine probe study on Lombok Island, Indonesia during 1998 "2002. Incidences were adjusted for limited access to care. Health system and patient out-of-pocket treatment cost data were collected concurrent with the probe study. For Hib vaccine in monovalent and combined (with DTP-HepB) presentations, we used 2007 UNICEF vaccine prices of US$3.30 and $3.75 per dose. Results: For the 2007 Indonesian birth cohort, Hib vaccine would prevent meningitis in 1 of every 179 children, pneumonia in 1 of every 18 children, and 4.9% of mortality among those younger than 5 years. The total incremental societal costs of introducing Hib vaccine in monovalent and pentavalent presentations were, respectively, US$11.74 and $8.93 per child vaccinated. Annual discounted treatment costs averted amounted to 20% of pentavalent vaccine costs. For the pentavalent vaccine, the incremental costs per discounted death and disability adjusted life-year averted amounted to US$3102 and $74, respectively, versus $4438 and $102 for monovalent vaccine. Conclusions: Routine infant Hib vaccination would prevent a large burden of pediatric illness and death in Indonesia. Even without external funding support, Hib vaccine will be a highly cost-effective intervention in either a monovalent or pentavalent presentation based on commonly used benchmarks.

KW - cost effectiveness

KW - Haemophilus influenzae type b

KW - Indonesia

KW - vaccine

KW - vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=45849099512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849099512&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e318165f1ba

DO - 10.1097/INF.0b013e318165f1ba

M3 - Article

C2 - 18398383

AN - SCOPUS:45849099512

VL - 27

SP - 438

EP - 443

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 5

ER -